期刊文献+

抗结核药物作用机制及构效关系的研究进展

Research advances on the activity mechanism and structure-activity relationships of anti-tuberculosis agents
原文传递
导出
摘要 在过去的几十年里,随着艾滋病(AIDS)的蔓延,结核病的发病率也在逐渐增多,除结核病外,由分支杆菌所引起的其他疾病也开始传播,HIV感染患者特别容易受分支杆菌的感染。该文主要对抗结核药物的作用机制以及构效关系(SARs)进行简要的综述,以便能更好的、合理的使用抗结核药物。 In the past few decades,with the prevalence of AIDS,tuberculosis has begun to comeback and spread.In addition to tuberculosis,diseases caused from Mycobacterium also began to become more prevalent,HIV-infected patients were particularly vulnerable to mycobacterial infections,incidence rate of such diseases and the resulting burden is very argent in the global.The mechanism and structure-activity relationships(SARs) of anti-tuberculosis agents were briefiy reviewed.
出处 《中国药物化学杂志》 CAS CSCD 2009年第5期382-389,共8页 Chinese Journal of Medicinal Chemistry
关键词 结核分支杆菌 肺结核 多重耐药性 活性机制 构效关系 Mycobacterium tuberculosis tuberculosis multi-drug resistance activity mechanism structure-activity relationships(SARs)
  • 相关文献

参考文献23

  • 1AMIT N,RAHUL J. Recent advances in new structural classes of anti-tuberculosis agents[ J]. Cult Med Chem,2005 ,12(16) :1873 - 1886.
  • 2ANDRIES K, JOZEF L, MARCEL K, et al. Quinoline derivatives for the treatment of latent tuberculosis: WO ,2006/7048 A1 [ P]. 2006 - 06 - 29.
  • 3刘伟,司书毅,肖春玲.新型抗结核药物的研究进展[J].国外医药(抗生素分册),2006,27(2):91-95. 被引量:8
  • 4JANIN Y L. Antituberculosis drugs: ten years of research [ J ]. Bioorg Med Chem, 2007, 15 ( 7 ) : 2479 - 2513.
  • 5TSUBOUCHI H, SASAKI H, HARAGUCHI Y, et al. Antituberculous activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo [ 2,1 -b ] oxazoles [ J ]. Antirnicrob Agents Chemother, 2005,49 (1) :16- 19.
  • 6WANG J H,ELCHERT B ,HUI Y,et al. Synthesis of trehalose-based compounds and their inhi-bitory activities against Mycobacterium smegmatis [ J]. Bioorg Med Chem,2004,12(24) :6397 -6413.
  • 7AHMED K K, SRINIVASA R S, KALEEM A M, et al. Anti-tubercular agents. Part 3. Benzothiadiazine as a novel scaffold for anti-Mycobacterium activity [ J ]. Bioorg Med Chem,2006,14 (3) :650 - 658.
  • 8IGARASHI M, NAKAGAWA N, DOI N, et al. Caprazamycin B, a novel anti-tuberculosis antibiotic, from Streptomyces sp [ J ]. J Antibiol, 2003,56 (6) : 580 - 583.
  • 9CYNAMON M H,KLEMENS S P,SHARP C A,et al. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model [ J ]. Anfimicrob Agents Chemother, 1999,43 (5) : 1189 - 1191.
  • 10XU Z Q, KRZYSZT P, WILLIAM J S, et al. Pyranocoumarin, a novel anti-TB pharmacophore: synthesis and biological evaluation against Mycobacterium tuberculosis[ J]. Bioorg Med Chem,2006, 14 (13) :4610 -4626.

二级参考文献39

  • 1陈国良,谭国良,孙平华.抗结核药物的研究与开发[J].药学进展,2004,28(12):529-537. 被引量:7
  • 2钟静,黄平,麦洁儿.新型抗结核病药物[J].中国热带医学,2005,5(2):399-400. 被引量:6
  • 3侯丽莉.治疗肺结核的新武器?[J].国外医学(药学分册),2005,32(3):209-210. 被引量:4
  • 4Scientific blueprint for TB drug development, the Global Alliance for TB Drug Development forum. 2001,1-52.
  • 5Andries K, Verhasseh P, Guilemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science, 2005, 307(5707):223-227.Epub 2004 Dec 9.
  • 6Igarashi M, Nakagawa N, Hattori S, et al. Caprazamycin A-F, novel anti-TB antibiotics from Streptomyces sp. (C)Abstr.42nd ICAAC,ASM.Washington,DC. Sept.2002:p.232.
  • 7Stover CK, Warrener P, VanDevanter DR, et al. A small molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature,2000,405(6789): 962-969.
  • 8McCune RM, Tompsett R ,McDermott. Fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. J.Exp.Med,1956,104:763-801.
  • 9Cole ST. Comparative mycobactefial genomics as a tool for drug target and antigen discovery. Eur Respir J, 2000,20Suppl.36:78s-86s.
  • 10MeKinney JD. In vivo veritas: the search for TB drug targets goes live. Nature Medieine,2000,6(12):1330-1333.

共引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部